Inhibition of MMP-9, the primary MMP implicated in stroke-induced neuroinflammation and the biphasic disruption of the blood–brain barrier, has shown mixed results in experimental studies depending on the timing of administration [102]. This evidence concerns the gene MMP9 and Stroke.